Commercial Reporting and Insights Analyst - Healthcare
About the job
- Experience in commercial analytics, business intelligence, sales operations, performance reporting, or a related analytical role.
- Hands-on experience building dashboards and recurring reports using Tableau or Power BI.
- Understanding of reporting concepts, including metrics, filters, hierarchies, targets, trend analysis, and data validation.
- Ability to use SQL, Excel, or comparable tools to analyse data, validate outputs, and investigate discrepancies.
- Ability to translate business questions into clear analyses, concise visualizations, and practical commentary.
- Ability to document logic, reconcile outputs, and maintain reporting consistency.
- Ability to collaborate with regional, country, business, data, and system stakeholders.
- Ability to manage recurring deadlines and follow through on open issues.
- Typically requires a Bachelor’s degree and a minimum of 2–5 years of related experience.
- Build, maintain, and improve standardized EMEA commercial performance dashboards and recurring reports aligned to agreed business definitions.
- Partner with Commercial Excellence, Analytics, Sales Operations, Finance, Marketing, and country teams to translate reporting needs into practical, reusable solutions.
- Support adoption of common key performance indicators, calculation rules, targets, filters, and reporting hierarchies across EMEA.
- Monitor trends, variances, and exceptions to surface material performance changes and areas requiring follow-up.
- Validate and reconcile reporting outputs, investigate inconsistencies, and coordinate resolution with data owners.
- Create clear summaries and visualizations that explain what changed, where it changed, and why it matters.
- Help rationalize existing reports and dashboards, reducing duplication and improving consistency across EMEA.
- Maintain reporting documentation, gather user feedback, support testing, and promote effective use of standardized reporting.
- Experience in MedTech, pharmaceutical, healthcare, or another regulated commercial environment.
About the company
Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1999
Get referred to Dexcom
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 13% to $1.308 billion; guidance reached $5.25 billion.
- Gross margin hit 64.1% in Q2 2026, up 400 basis points year-over-year.
- G7 15 Day shipments and Stelo AI updates deepen retention before G8's 2027 launch.
What critics are saying
- FDA flagged stolen G7 lots in May 2026, exposing sterilization and failure-control lapses.
- Dexcom faces consumer, wrongful-death, and securities suits over G6/G7 accuracy claims.
- A major recall or injunction would shatter pharmacy trust and halt Dexcom's U.S. growth.
What makes Dexcom unique
- FDA-cleared G7 15 Day in 2026 stretches wear beyond Abbott FreeStyle Libre 3.
- Dexcom Stelo and G7 integrate with Oura, Omnipod 5, Tandem, and NovoPen.
- Dexcom's APAC Health2Sync platform extends CGM into chronic-care workflows across Australia and Singapore.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Remote Work Options
Flexible Work Hours
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Heidi rolls out AI agents and more briefs. Also, Dexcom and Health2Sync are extending their integrated CGM offering to Australia and Singapore. By Adam Ang | October 2, 2026 | 12:59 AM Heidi introduces AI agents Heidi has unveiled the latest version of its AI platform with AI agents that perform administrative tasks around patient visits. The upgraded platform features new AI agents that can plan and execute tasks such as pre-charting, referral communications, panel reviews and follow-up work across EHRs, calendars, inboxes and patient portals. Heidi maintained that clinicians retain approval and control over decision-making. Heidi II rollout began in late September in English and French outside the United Kingdom and European Union. Dexcom, Health2Sync expand APAC integration CGM maker Dexcom and Taipei-based Health2Sync are expanding their diabetes technology partnership to Australia and Singapore, extending an existing collaboration in Japan. The collaboration offers Health2Sync's digital platform that can be integrated with Dexcom's continuous glucose monitoring (CGM) data. The integrated offering will go live in the "next few months," Dexcom said in a LinkedIn post. Qld AI launchpad bags fed grant Queensland University of Technology (QUT) researchers have received an A$1.49 million (about $1 million) federal government grant to develop and evaluate AI launchpads intended to help health services implement and sustain AI in routine care. According to a media release, the project will work with clinicians, consumers, digital health researchers and industry to build local systems and workforce capabilities for procuring proprietary AI, adapting tools from other health services and developing and evaluating AI within health service environments. Partners include health services: Metro South, Children's Health Queensland, Sunshine Coast, West Moreton, Mackay, Queensland Health, as well as Microsoft Australia and the Australian Institute of Digital Health.
Dexcom promotes Jereme Sylvain to Chief Operating Officer. Key Takeaway: Dexcom has announced the promotion of Jereme Sylvain to Chief Operating Officer. This strategic move is expected to bolster the company's operational capabilities and drive future growth. Sylvain's leadership is anticipated to play a crucial role in advancing Dexcom's objectives. Market sentiment analysis. Positive factors. * Jereme Sylvain's promotion reflects confidence in leadership. * The move may enhance operational efficiency at Dexcom. * This change could positively impact company direction. SAN DIEGO-(BUSINESS wire)-dexcom promotes Jereme Sylvain to Chief Operating Officer. Frequently asked questions. Who was promoted to Chief Operating Officer at Dexcom? Jereme Sylvain has been promoted to Chief Operating Officer at Dexcom. What is the significance of Jereme Sylvain's promotion? His promotion is expected to enhance operational efficiency and company growth.
Quentin Blackford to join Align Technology Board of Directors. Andrea L. Saia to Retire After 13 Years of Service Quentin Blackford TEMPE, Ariz. & SAN JOSE, Calif.-(BUSINESS WIRE)-Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign(R) System of clear aligners, iTero(TM) intraoral scanners, and exocad(TM) CAD/CAM software for digital orthodontics and restorative dentistry, today announced that its Board of Directors has appointed Quentin Blackford, President and Chief Executive Officer of iRhythm Technologies, as a director effective immediately and announced the retirement of Andrea Saia effective September 23, 2026. "We are pleased to welcome Quentin Blackford to our Board," said Kevin Conroy, Chairman of the Board of Align Technology. "Quentin is an exceptional leader whose accomplishments in global healthcare, medical technology, and digital innovation speak for themselves. His breadth of experience, strategic judgment, and commitment to advancing patient care will be tremendous assets to Align as we continue to shape the future of digital dentistry around the world." Mr. Blackford currently serves as President and Chief Executive Officer of iRhythm Technologies, a leading digital healthcare company focused on advancing cardiac care. He has served in this role since 2021. Before joining iRhythm, Mr. Blackford served as Chief Operating Officer of Dexcom, where he helped lead the company's global operations, corporate strategy, and international growth initiatives. Previously, he held senior finance and leadership positions at NuVasive and Zimmer Holdings. Mr. Blackford currently serves on the board of Alphatec Holdings and is a Certified Public Accountant (inactive). He earned dual Bachelor of Science degrees in Accounting and Business Administration from Grace College. Since joining the Board in 2013, Ms. Saia has played an important role in supporting Align's growth and transformation as a global medical device and digital dentistry leader. Her insights and counsel have contributed to the Board's oversight of the Company's strategic priorities, governance practices, and long-term growth initiatives. The Board and management team extend their sincere appreciation for her dedicated service and many contributions to Align. "Andrea has been an exceptional member of our Board and a trusted advisor to management," said Joe Hogan, president and CEO of Align Technology. "Her deep expertise, thoughtful counsel, and unwavering commitment to strong governance have helped guide Align through a period of significant growth and innovation. On behalf of the Board and the entire Align team, I want to thank Andrea for her many contributions and years of dedicated service." Mr. Blackford will be included in the company's slate of director nominees in the proxy statement for Align's 2027 Annual Meeting of Shareholders. In connection with Mr. Blackford's appointment, the Board increased its size to 11 directors. Effective upon Ms. Saia's resignation from the Board in September 2026, the size of the Board will decrease and again be comprised of ten directors. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign(R) System, the most advanced clear aligner system in the world, iTero(TM) intraoral scanners and services, and exocad(TM) CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 302.0 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 23.5 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align(TM) Digital Platform, its integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information. For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com. Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Dexcom, Health2Sync partner on diabetes care in Asia. Mon, 24th Aug 2026 (Today) Dexcom and Health2Sync have formed a partnership focused on diabetes care in Australia and Singapore, linking glucose monitoring with digital chronic disease management. The partnership aims to support more connected care for people living with diabetes and their healthcare providers in both markets. It also reflects a broader push to expand digital health tools across Asia-Pacific. Health2Sync operates a digital chronic disease management platform that supports about 1.7 million users across the region. The company has built a presence in several Asian markets by offering tools that help people with diabetes and healthcare teams manage long-term care through digital services. Dexcom is known for its continuous glucose monitoring systems, which track glucose levels for people living with diabetes. The tie-up with Health2Sync reflects growing demand for connected healthcare technologies that support care coordination, simplify clinical workflows and enable more tailored approaches to chronic disease management. Regional push The deal gives Dexcom another partnership in Asia-Pacific as digital health companies seek to integrate monitoring devices with software platforms used by patients and clinicians. Australia and Singapore are both exploring greater use of remote monitoring and data-driven management for chronic conditions. Diabetes remains a major long-term health issue across the region, driving demand for systems that connect patient data with clinical decision-making. Companies in the sector have increasingly focused on linking devices, apps and care teams rather than offering standalone products. Health2Sync's scale in the region may give Dexcom access to a wider digital care network, while Dexcom's monitoring products add a stream of glucose data that can be incorporated into patient management. The companies have not disclosed commercial terms or product integration details. The announcement did not specify which Dexcom products or Health2Sync services would be included first in Australia and Singapore. It also did not say when any integrated offering would become available to users or healthcare providers. Company comments Both companies framed the partnership around a shared view that diabetes care can benefit from more connected management models. They said the arrangement is intended to help healthcare professionals and people living with diabetes access smarter, more connected ways to manage the condition. No financial details were released. The companies also did not outline any regulatory steps, local distribution arrangements or clinical partnerships tied to the agreement. More information is expected later. For now, the main disclosed fact is that Dexcom and Health2Sync are aligning their diabetes-related offerings across Australia and Singapore.
Silvant Capital Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 79,562 shares of the medical device company’s stock, valued at approximately $5,359,000. Other large investors have also recently modified their holdings of the company. Reflection Asset Management acquired a new […]